The newer antimuscarinic drugs: Bladder control with less dry mouth

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 10, 2002, Pages 761-769

  Appell, Rodney A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; DETROL XL; DICYCLOVERINE; IMIPRAMINE; KETOCONAZOLE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; TOLTERODINE; UNCLASSIFIED DRUG;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BLADDER DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; HEAT TOLERANCE; HUMAN; OVERACTIVE BLADDER; SALIVATION; URGE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0036798614     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.10.761     Document Type: Article

References (19)

1. Appell RA, Sand P, Dmochowski R, et al. Prospective, randomized, controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76:358-363.
2. Appell R. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50(suppl):90-96.
3. Chancellor M, Freedman S, Mitcheson HD. Tolterodine, an effective and well-tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000; 19:83-91.
4. Rentzhog L, Stanton SL, Cardozo L, et al. Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study. Br J Urol 1998; 81:42-48.
5. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81:801-810.
6. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine: a novel bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327:195-207.
7. Van Kerrebroeck PE. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder [abstract]. Neurourol Urodyn 2000; 19:493.
8. Van Kerrebroeck PE, Kreder K, Jonas U, et al. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57:414-421.
9. Dmochowski R. The effect of pH on drug release from extended-release formulations of oxybutynin and tolterodine. 2nd International Consultation on Incontinence of the World Health Organization. Paris, July 2001.
10. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite N-desethyloxybutynin in the human detrusor and parotid gland. J Urol 1997; 157:1093-1097.
11. Chancellor MB, Sathyan G, Gupta SK. Effect of ketoconazole on the pharmacokinetics of oxybutynin: comparison between an extended-release oxybutynin and conventional oxybutynin [abstract]. Neurourol Urodyn 1999; 18:374.
12. Anderson RU, Mobley D, Blank B, et al. Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161:1809-1812.
13. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54:420-423.
14. Appell R, Diokno A, Antoci J, et al. One-year, prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population [abstract]. Neurourol Urodyn 2000; 19:528.
15. Tuttle J, Antoci J, Appell RA, et al. Controlled-release oxybutynin for overactive bladder in an elderly population. Proceedings of the American Geriatric Society, Nashville, Tenn; September 2000.
16. Chamberlain TM, Stephenson DW, Appell RA, et al. Urinary incontinence in the long-term care patient. Consultant Pharmacist 1990; 5:173-178.
17. Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000; 56(suppl 6A):41-49.
18. Versi E, Appell RA, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95:718-721.
19. Chancellor MB, Appell RA, Sathyan G, et al. Effect on salivary output following controlled-release oxybutynin and tolterodine [abstract]. Neurourol Urodyn 2000; 19:494.